Results 201 to 210 of about 966,835 (308)

Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia

Arthritis Care &Research, EarlyView.
Objective Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia. Methods Participants in a multinational study of
Nicola Dalbeth, Sarah Stewart, Gregory D. Gamble, Borislav Mihov, Lisa K. Stamp, Janine Haslett, William J. Taylor, Tony R. Merriman, Adwoa Dansoa Tabi‐Amponsah, Anne Horne, Tuhina Neogi, Tristan Pascart, Mariano Andrés, Maria‐Luisa Peral‐Garrido, Eleonora Norkuviene, Janitzia Vazquez‐Mellado, Till Uhlig, Mingshu Sun, Changgui Li, Keith J. Petrie   +19 more
wiley   +1 more source

Assessment of the feed additives menadione sodium bisulphite (3a710) and menadione nicotinamide bisulphite (3a711) (vitamin K₃) for all animal species for the renewal of their authorisation (DSM Nutritional Products Ltd, KH Boddin GmbH, Oxyvit Kimya San. Ve Tic. A.Ş., Orffa Additives BV, FNF Ingredients EU BV, ADM International SàRL). [PDF]

EFSA J
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Villa RE, Azimonti G, Bonos E, Christensen H, Durjava M, Dusemund B, Gehring R, Glandorf B, Kouba M, López-Alonso M, Marcon F, Nebbia C, Pechová A, Prieto-Maradona M, Röhe I, Theodoridou K, Ørnsrud R, Galobart J, Manini P, Navarro-Villa A, Pizzo F, Vettori MV, Gkimprixi E.   +23 more
europepmc   +1 more source

Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

Arthritis Care &Research, EarlyView.
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Kristine (Pek Ling) Ng, Annie Law, B. M. D. B. Basnayake, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Shirley Chan, C. S. Lau, Vera Golder, Alberta Hoi, Shereen Oon, Eric Morand, Mandana Nikpour, for the Asia‐Pacific Lupus Collaboration   +39 more
wiley   +1 more source

Morphology-modified contributions of electronic transitions to the optical response of plasmonic nanoporous gold metamaterial. [PDF]

Nat Commun
Tapani T, Pettersson JM, Henriksson N, Brunner CM, Zimmermann AC, Zäll E, Hauff NV, Das L, Sapunova A, Balestra G, Cuscunà M, De Andrés A, Giovannini T, Garoli D, Maccaferri N.   +14 more
europepmc   +1 more source

Impact of Positive Lifestyle Behaviors on Direct Health Care Cost Savings for Low Back Pain

Arthritis Care &Research, EarlyView.
Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and health care cost savings related to low back pain (LBP). Methods This longitudinal study used data from the Australian Twin Back (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline. Physical activity
Ye Tian, Katharine E. Roberts, Michelle Hall, Paula R. Beckenkamp, Angelo Sabag, Karoline Moe, Ana Paula Carvalho‐e‐Silva, Emily J. Callander, Paulo H. Ferreira   +8 more
wiley   +1 more source

Reversible Enzymatic Switching of the Oxidation State of a Eu^III/II Complex Controls Relaxivity. [PDF]

J Am Chem Soc
Sarson ET, Cooper SM, Sedgwick AC, Berger AG, Twigger SA, Hammond EM, Vincent KA, Faulkner S.   +7 more
europepmc   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Assessment of genetically modified maize MON 87460 for renewal authorisation under Regulation (EC) No 1829/2003 (dossier GMFF-2023-21251). [PDF]

EFSA J
EFSA Panel on Genetically Modified Organisms (GMO), Casacuberta J, Barro F, Braeuning A, de Maagd R, Epstein MM, Frenzel T, Gallois JL, Koning F, Messéan A, Moreno FJ, Nogué F, Savoini G, Schulman AH, Tebbe C, Veromann E, Camargo AM, Goumperis T, Lenzi P, Piffanelli P, Raffaello T, Sánchez-Brunete E.   +21 more
europepmc   +1 more source

Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective Pulmonary fibrosis (PF) is a severe extra‐articular manifestation of rheumatoid arthritis (RA). This study aimed to externally validate a genetic risk score (GRS) and a combined risk score (CRS) for predicting the risk of RA‐associated PF in an independent cohort of patients with early RA.
Mikael Brink, Austin Wheeler, Bryant R. England, Solbritt Rantapää‐Dahlqvist   +3 more
wiley   +1 more source

Safety of an extension of use of pasteurised <i>Akkermansia muciniphila</i> as a novel food pursuant to Regulation (EU) 2015/2283. [PDF]

EFSA J
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, De Henauw S, Jos Á, Maciuk A, Mangelsdorf I, McNulty B, Naska A, Pentieva K, Siani A, Thies F, Aguilera-Gómez M, Frenzel T, Marcon F, McArdle HJ, Moldeus P, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Ackerl R, Hirsch-Ernst KI.   +26 more
europepmc   +1 more source